Product
Efgartigimod PH20
3 clinical trials
2 indications
Indication
Myasthenia GravisIndication
bioequivalenceClinical trial
An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod PH20 SC in Participants From 2 to Less Than 18 Years of Age With Generalized Myasthenia GravisStatus: Not yet recruiting, Estimated PCD: 2026-09-30
Clinical trial
A Long-Term, Single-Arm, Open-label, Multicenter Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia GravisStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase 1, Randomized, Open-label, Parallel-Group, Single-Dose, Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial + Syringe Presentation in Healthy AdultsStatus: Completed, Estimated PCD: 2023-05-12